Oftalek solution for infection. 10mg/ml amp. 1 ml No. 10

Structure and form of release

Structure

Active ingredient: methylethylpiridinol hydrochloride;

1 ml of solution;

excipients: divorced Acidum hydrochloricum, water for injections.

a release Form

Solution for injections.

Pharmacological properties

Pharmacodynamics. Oftalek stabilizes a cellular membrane, inhibits aggregation of thrombocytes and neutrophils, reduces the index of coagulation, extends a blood clotting time, reduces viscosity of blood, has fibrinolytic activity, increases the maintenance of cyclic nucleotides in fabrics, reduces permeability of a vascular wall. Oftalek also shows angioprotektorny properties, protects a retina from damages at influence of light of high intensity, improves microcirculation.

Pharmacokinetics. Oftalek is brought from an organism generally with urine and in insignificant quantities - in not changed look. At retrobulbar introduction Oftalek almost instantly appears in blood; within the first 2 hours its concentration sharply decreases, and in 24 hours medicament in blood is absent. In eye tissues Oftalek's concentration is higher, than in blood.

Indication

• Subconjunctival and intraocular hemorrhages of various genesis.
Angioretinopatiya's
• (including a diabetic retinopathy).
• Central and peripheral chorioretinal dystrophies.
• Fibrinferments of the central vein of a retina and its branches.
• Complicated myopathy.
• Angiosclerotic makulodistrofiya (dry form).
• Amotio of a choroid at patients with glaucoma during the postoperative period.
• Dystrophic diseases of a cornea.
• Injury, cornea burns.
• Protection of a cornea (at use of contact lenses) and eye retinas from influence of light of high intensity (sunshine, laser radiation at a lazerkoagulyation).

Contraindication.

Hypersensitivity to drug.

Route of administration and doses

enter Solution of an oftalek subkonjyunktivalno or parabulbarno. if necessary perhaps retrobulbar introduction. subkonjyunktivalno enter 0.2 - 0.5 ml (2 - 5 mg), parabulbarno - 0.5 - 1 ml (5 - 10 mg) of 1% of solution. medicament is used within 10 - 30 days of 1 times a day or every other day. if necessary it is possible to repeat treatment 2 - 3 times a year. retrobulbarno enter 0.5 - 1 ml of medicament of 1 times a day within 10 - 15 days.

For protection of a retina at a lazerkoagulyation (especially at a lazerkoagulyation which limits or destroys a tumor) parabulbarno or retrobulbarno in 24 hours and in 1 hour prior to the procedure, and then - in the same doses (on 0.5 ml of 1% of solution) 1 time a day within 2-10 days.

Children

do not use Drug to children.

In some cases, especially at predisposed patients, at patients with bronchial asthma at hypersensitivity to sulfites, development of heavy reactions of hypersensitivity is possible

Feature of use.

to

Use during pregnancy or feeding by a breast

use of medicament during pregnancy and feeding by a breast.

Ability to influence speed of response at control of motor transport or other mechanisms

Should be careful at control of motor transport or other mechanisms as medicament can cause drowsiness, increase in arterial blood pressure.

Cases of overdose are not described by

. At overdose strengthening of side effects of drug, disturbance of blood clotting is possible. treatment: to cancel drug, symptomatic therapy.

Side reactions

Short-term arousing, drowsiness, increase in arterial blood pressure, allergic reactions (skin rashes, an itching, reddening), local reactions - pain, burning and consolidation of paraorbital fabrics (resolves by itself).

Interaction

Negative manifestations at use of an oftalek against the background of therapy by other medicines it is not described. α-tocopherol acetate exponentiates antioxidant effect of an oftalek. It is impossible to mix solution of an oftalek in one syringe with other drugs.

to Store

in original packing at a temperature not above 25 °C. to store out of children's reach. An expiration date - 2 years.